Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rapid dose escalation with quetiapine: a pilot study.

Mark A Smith1, Robin McCoy, Jennifer Hamer-Maansson

  • 1AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, PO Box 15437, Wilmington, DE 19850, USA.

Journal of Clinical Psychopharmacology
|July 14, 2005
PubMed
Summary

Faster quetiapine dosing is safe for schizophrenia treatment. This pilot study found that escalating to 400 mg/day in 2 or 3 days, instead of 5, showed similar safety and tolerability in acute schizophrenia patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Modification of amyloid-β1-42 fibril structure by methionine-35 oxidation.

Journal of Alzheimer's disease : JAD·2013
Same author

Dietary choice affects Shiga toxin-producing Escherichia coli (STEC) O157:H7 colonization and disease.

Proceedings of the National Academy of Sciences of the United States of America·2013
Same author

Sequestration of p27 within the cytoplasm of cardiac myocytes in chronic ischemic heart disease: pathogenic implications for ischemic cardiomyopathy.

Age (Dordrecht, Netherlands)·2013
Same author

Structure, recombinant expression and mutagenesis studies of the catalase with oxidase activity from Scytalidium thermophilum.

Acta crystallographica. Section D, Biological crystallography·2013
Same author

Modeling the heterogeneity in risk of progression to Alzheimer's disease across cognitive profiles in mild cognitive impairment.

Alzheimer's research & therapy·2013
Same author

Virulence of the Shiga toxin type 2-expressing Escherichia coli O104:H4 German outbreak isolate in two animal models.

Infection and immunity·2013

Area of Science:

  • Psychiatry
  • Pharmacology
  • Clinical Trials

Background:

  • Schizophrenia treatment often requires rapid symptom control.
  • Standard quetiapine dosing recommendations involve a 5-day escalation to 400 mg/day.
  • Clinicians frequently use faster titration schedules to achieve therapeutic effects sooner.

Purpose of the Study:

  • To evaluate the safety and tolerability of accelerated quetiapine dosage escalation in acutely ill schizophrenia patients.
  • To compare 5-day, 3-day, and 2-day titration schedules to a target dose of 400 mg/day.

Main Methods:

  • Multicenter, placebo-controlled, double-blind pilot study.
  • Adult patients with acute schizophrenia were randomized to three different quetiapine dose-escalation schedules.
  • Safety and tolerability assessed via interviews, physical exams, vital signs, labs, and ECGs.

Related Experiment Videos

Main Results:

  • Treatment-related adverse events were infrequent and mostly mild across all groups.
  • Only 3 out of 69 patients withdrew due to adverse events (agitation).
  • No significant differences in objective assessments or adverse events were observed between the 5-day, 3-day, and 2-day escalation groups.

Conclusions:

  • Accelerated titration of quetiapine to 400 mg/day in 2 or 3 days is safe and well-tolerated in acute schizophrenia.
  • Faster dose escalation can be achieved without compromising patient safety or tolerability.
  • These findings support the potential for more rapid achievement of therapeutic quetiapine dosages.